Epione®, Quantum Surgical’s medical robot, settled in Hospices Civils de Lyon (HCL)
.jpg)
Montpellier, France November 16th, 2022 - Civil Hospitals of Lyon, France (HCL ) have aquired Epione, the robotic platform developed by Quantum Surgical (QS) that is designed to enable minimally invasive ablations of tumors in the abdomen. This partnership between HCL and QS will allow more patients to benefit from Epione, an innovative platform allowing physicians to plan, target, deliver and confirm ablation treatment in a moresecure and precise manner. Epione is currently utilized to target liver tumors but will be expanded to the treatment of kidney, lungs and pancreas as the radiologists at CHU Lyon expand their robotic interventional oncology practice.
HCL ranks asthe second largest University hospital in France and represents the second hospital in the world to offer this groundbreaking platform. The first Epione robot was acquired by Gustave Roussy in January 2022 and the team is approaching their 100throbotic procedure.
"This new acquisition of Epione is a major step for QS and a full validation of the key benefits that Epione offers. It is a great honor to have our robotic system acquired by one of the top medical robotic institutions in France. The most exciting part of this story is that patients will now have a powerful new technology that can offer curative treatments by robotically navigating to destroy tumors while sparing surrounding healthy tissue" says Bertin Nahum, co-founder and CEO of Quantum Surgical.
"Epione® is a unique percutanueous robotic solution […] Currently only few experts radiologists perform these treatments. Robotics will allow to standardize these treatments and more radiologists will thus be able to perform these cases especially the more complex cases on tumors which currently would not be treated . This will allow us to help and cure more patients" says Pr. Laurent Milot, deputy Head of Medical and interventional imagingDepartment- CHU Lyon.